S282
Clinical - Breast
ESTRO 2026
with secondary or higher education. Conclusion: This study highlights the persistence of
Digital Poster Highlight 2603 Sexual dysfunction in long-term breast cancer survivors: Insights from a LMIC country Nejla Fourati 1 , Imene Baati 2 , Emna Ben Amar 3 , Eya Triki 3 , Wicem Siala 1 , Jaweher Masmoudi 2 , Jamel Daoud 1 1 Radiotherapy Department Habib Bourguiba Hospital, Faculty of Medicine University of Sfax, Sfax, Tunisia. 2 Psychiatry A Department Hedi Chaker Hospital, Faculty of Medicine University of Sfax, Sfax Tunisia, Sfax, Tunisia. 3 Higher Institute of Human Sciences, University of Tunis, Tunis, Tunisia Purpose/Objective: Sexual health is an integral yet underaddressed component of cancer survivorship, particularly in low- and middle-income countries (LMICs), where sociocultural barriers and limited supportive care hinder its evaluation and management. Breast cancer treatments can profoundly affect sexual function, but long-term quantitative data from these settings remain scarce.This study aimed to assess sexual function using the Female Sexual Function Index (FSFI) among breast cancer survivors in prolonged remission and to identify associated factors. Material/Methods: This cross-sectional study included 58 women in long- term remission after curative treatment for non- metastatic breast cancer. Sociodemographic and clinical data were collected. Sexual function was evaluated using the validated Arabic version of the FSFI, comprising 19 items exploring six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain.As all FSFI variables showed non-normal distributions (Shapiro–Wilk < 0.05), results were expressed as medians [min–max]. A total FSFI score below 26.55 was considered indicative of sexual dysfunction. Associations between categorical variables and the presence of sexual dysfunction were tested using the Chi-square ( χ² ) test. Results: The median age of participants was 50 years [23–71], and the median timesince diagnosis was 42 months [14–276]. Half of the women had undergone conservative surgery (50%), and 48.3% lived in urban areas. The median total FSFI score was 16 [1–34]. Median domain scores were 2 [1–6] for desire, 2 [0–6] for arousal, 2 [0–6] for lubrication, 2.5 [0–6] for orgasm, 2 [0–6] for satisfaction, and 3 [0–5] for pain.Overall, 43 out of 58 participants (74.1%) met the criteria for sexual dysfunction. The prevalence of dysfunction did not significantly differ by residence (urban vs rural; p = 0.46) or surgical type (conservative vs radical; p = 0.13). In contrast, a significant association was found with educational level (p = 0.03): sexual dysfunction affected 84.8% of women with no or primary education compared with 60% of those
multidimensional sexual dysfunction among long-term breast cancer survivors in a LMIC context, even several years after completing treatment. The association between sexual dysfunction and low educational attainment underscores the importance of awareness, communication, and empowerment in sexual recovery. These findings emphasize the need to integrate structured sexual health assessment, counseling, and rehabilitationinto survivorship care programs in resource-limited settings, where follow-up often remains focused solely on oncologic outcomes rather than holistic well-being. Keywords: Breast cancer, sexual health ultra hypofractionated breast radiation therapy with single boost dose for breast cancer; Physician and patient reported outcomes. NCI, Cairo, Egypt. Marwa M Rostom, nagwan ibrahim anter, Medhat Mohamed El Sebaie radiation oncology and nuclear medicine, national cancer institute, cairo, Egypt Purpose/Objective: Radiotherapy is pivotal in treating breast cancer. Moderately hypofractionated radiation therapy (MHF), typically prescribed as a 2.67 Gy daily dose to the breast/chest wall with or without irradiation of the regional lymph nodes, delivered in 15 to 16 daily fractions, is standard after breast surgery, oAering comparable eAicacy to longer regimens but with shorter treatment times. The FAST and FAST-Forward studies explored hypofractionated radiotherapy (HFRT) beyond moderately hypofractionated schedules. In busy departments and low resources countries; the application of ultra hypofractionation is more convenient and cost effective. Our study aims to assess the different outcomes of the ultrahypofractionated course in a cohort of early stage breast cancer post breast conservative surgery. Material/Methods: Digital Poster 2617 This retro prospective study evaluated physician- and patient-reported outcomes of ultra hypofractionated breast radiation therapy with a single-fraction boost to the tumor bed; Conducted at the National Cancer Institute’s breast cancer hospital, included 82 female breast cancer patients treated using the FAST protocol: 28.5 Gy over five weekly fractions, with an additional 5.7 Gy boost for high-risk patients (grade III tumors or age <50 years). Late toxicities were assessed using the CTCAE, cosmetic scores were measured using BCCT.core3.1 AI based software while patient
Made with FlippingBook - Share PDF online